europass Curriculum vitae

PERSONAL INFORMATION

Siri Wang

WORK EXPERIENCE

October 2014–Present

Scientific Director

Norwegian Medicines Agency (Norway)

Norwegian PDCO delegate (2007-)

Paediatric related activities (national and international)

Teaching activities

Supervising PhD and MSci students

July 2007–September 2014

Senior Advicer

Norwegian Medicines Agency (Norway)

Norwegian PDCO delegate (2007-)

Paediatric related activities (national and international)

Chair of PDCO's Formulation Working Group 2008-2013

Teaching activities

Supervising PhD and MSci students

July 2000–September 2010

Hospital Pharmacist

Tønsberg Hospital Pharmacy, Vestfold Hospital Trust (Norway)

Contact pharmacist / ward pharmacist at the Paediatric Unit, Vestfold Hospital Trust.

Clinical pharmacist at the Geriatric Unit (2006-), Vestfold Hospital Trust

Lecturer: Teaching pharmacokinetics, drug interactions, paediatric pharmacy, and general pharmacology and therapeutics to pharmacists, nurses, neonatal nurses, pharmacy students, ICU nurses

Member of EMEA Paediatric Working Party (PEG) (2005-2007)

1989–1995

Scientific assistant / PhD student

School of Pharmacy, University of Oslo (Norway)

Research

Lecturing

1995–2000

Hospital Pharmacist / Assistant Chief Pharmacist

Haugesund Hospital Pharmacy (Norway)

EDUCATION AND TRAINING

1989–2000

PhD Pharmacy/Pharmacology

Dep of Pharmacology, School of Pharmacy, University of Oslo (Norway)

Concentrations: Pharmacology / Pharmacokinetics

Dissertation: Aspects of ascorbic acid kinetics: In vivo and in vitro studies with focus on methodology

1984–1990

Ms Sci Pharmacy

School of Pharmacy, University of Oslo (Norway)

Concentration: Pharmacology

ADDITIONAL INFORMATION

Expertise

Pharmacology
Pharmacokinetics
Paediatric pharmacy
Formulations
Geriatrics
Drug interactions
Clinical pharmacology
Paediatric drug development

Publications

Blume J, Ruano AL, Wang S, Jackson DJ, Tylleskär T, Strand LI. (2018) Oral medicine acceptance in infants and toddlers: measurement properties of the caregiver-administered Children's acceptance tool (CareCAT). BMC Pediatr. Mar 22;18(1):117. doi: 10.1186/s12887-018-1080-4.

Ternik R, Liu F, Bartlett JA, Khong YM, Thiam Tan DC, Dixit T, Wang S, Galella EA, Gao Z, Klein S. (2018) Assessment of swallowability and palatability of oral dosage forms in children: Report from an M-CERSI pediatric formulation workshop. Int J Pharm. Feb 5;536(2):570-581 doi: 10.1016/j.ijpharm.2017.08.088.

Bjerknes K, Bøyum S, Kristensen S, Brustugun J, Wang S. (2017) Manipulating tablets and capsules given to hospitalised children in Norway is common practice. Acta Paediatr. Mar;106(3):503-508. doi: 10.1111/apa.13700

Staven V, Iqbal H, Wang S, Grønlie I, Tho I. (2016) Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol. Oct 7. doi: 10.1111/jphp.12647.

Teigen A, Wang S, Truong BT, Bjerknes K. (2016) Off-label and unlicensed medicines to hospitalised children in Norway. J Pharm Pharmacol. Jun 23. doi: 10.1111/jphp.12581. [Epub ahead of print]

Staven V, Wang S, Grønlie I, Tho I. (2016) Development and evaluation of a test program for Y-site compatibility testing of total parenteral nutrition and intravenous drugs. Nutr J. Mar 22;15:29

Wang S (2015) Formulations in paediatric investigation plans (PIPs): Introduction to PIP quality section and regulatory framework. Int J Pharm. Aug 15;492(1-2):332-4

Staven V, Waaseth M, Wang S, Grønlie I, Tho I (2015). Utilization of the tyndall effect for enhanced visual detection of particles in compatibility testing of intravenous fluids: validity and reliability. PDA J Pharm Sci Technol. Mar-Apr;69(2):270-83

Wang S, Huemer K-H (2014) Paediatric pharmaceutical legislation and its impact on adult and padiatric drug development: The EU regulatory view. In: D. Bar-Shalom and K. Rose (eds.), Pediatric Formulations: A Roadmap, AAPS Advances in the Pharmaceutical Sciences Series 11, American Association of Pharmaceutical Scientists 2014.

Quijano Ruiz B, Desfontaine E, Arenas-López S, Wang S (2014) Pediatric formulation issues identified in Paediatric Investigation Plans. Expert Rev Clin Pharmacol. Jan;7(1):25-30

van Riet Nales DA, Kozarewicz P, Wang S, Saint-Raymond A, Robert JL (2013) Comments on the EMA draft guideline: Final steps towards a harmonized view between regulators and industry. Int J Pharm. 457 (1): 337-339

Wang S (2012) Suitable formulations for children [Egnede legemiddelformer for barn]. Norwegian Pharmaceutical Journal [Norsk Farmaceutisk Tidsskrift] 3: 12–16 (English abstract)

van Riet-Nales DA, Wang S, Saint-Raymond A, Robert JL. (2012) The EMA quality guideline on the pharmaceutical development of medicines for paediatric use. Int J Pharm. 5;435(2):132-4

Wang S, Laitinen-Parkkonen P. (2011) Efficacy assessment in paediatric studies.Handb Exp Pharmacol. 205:149-68

Wang S, Berge GE, Sund RB. (2001) Plasma ascorbic acid concentrations in healthy dogs. Res Vet Sci 71(1): 33-5

Wang S, Hoem NO, Berge GE, Sund RB (2001) Pharmacokinetics in dogs after oral administration of two different forms of ascorbic acid. Res Vet Sci 71(1): 27-32

Wang S, Eide TC, Sogn EM, Berg KJ (1999) Plasma ascorbic acid in patients undergoing chronic haemodialysis. Eur J Clin Pharmacol 55, 527-532

Meltzer HM, Folmer M, Wang S, Lie Ø, Maage A, Mundal HH, Ydersbond TA (1997) Supplementary

selenium influences the response to fatty acid induced oxidative stress in humans. Biol Trace Elem Res 60, 51-68

Mathiesen L, Wang S, Halvorsen BE, Malterud KE, Sund RB (1996) Inhibition of peroxidation in low density lipoprotein by the flavonoid myrigalon B and ascorbic acid. Biochem Pharmacol 51, 1719-1725

Christensen H, Andrew E, Berg KJ, Gedde-Dahl A, Karlsrud TS, Wang S (1995) Using problem-based learning in the pharmacotherapy teaching at the Institute of Pharmacy, University of Oslo. [Bruk av problembasert læring i farmakoterapi-undervisningen ved Farmasøytisk institutt]. Norwegian Pharmaceutical Journal

Wang S, Schram IM, Sund RB (1995) Determination of plasma ascorbic acid by HPLC: method and stability studies. Eur J Pharm Sci 3, 231-239

Projects

Academic research projects:

1. Challenges in daily infant pre-exposure prophylaxis to HIV exposed uninfected infants during breastfeeding (Centre for International Health, University of Bergen, Norway) (publicly funded,co-supervisor)

2. Medicines acceptability in children - study to increase the knowledge on which factors that affects medicines acceptability in the paediatric population in Norway, using a standardized assessment tool (University of Oslo, Norway, and ClinSearch, France)

Memberships

Other Relevant Information